<!doctype html>
<html lang="en">
<head>
	<meta charset="UTF-8">
	<meta name="viewport"
				content="width=device-width, user-scalable=no, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0">
	<meta http-equiv="X-UA-Compatible" content="ie=edge">
	<title>Farmina</title>

	
	<!-- Main style -->
	<link rel="stylesheet" href="css/normalize.css"/>
	<link rel="preconnect" href="https://fonts.googleapis.com">
	<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
	<link href="https://fonts.googleapis.com/css2?family=Mulish:wght@400;600;700&display=swap" rel="stylesheet">
	<link rel="stylesheet" href="css/jquery.fancybox.min.css"/>
	<link rel="stylesheet" type="text/css" href="css/nice-select.css"/>
	<link rel="stylesheet" type="text/css" href="css/swiper.min.css"/>
	<link rel="stylesheet" type="text/css" href="css/intlTelInput.min.css"/>
	<link rel="stylesheet" type="text/css" href="css/aos.css"/>
	<link rel="stylesheet" type="text/css" href="css/styles.css"/>
	<link rel="stylesheet" type="text/css" href="css/responsive.css"/>
	
</head>
<body>

  <header>
		<div class="top-line">
			<div class="content-width">
				<div class="logo-wrap">
					<a href="index.html">
						<img src="img/logo.svg" alt="">
					</a>
				</div>
				<nav class="top-menu">
					<ul>
						<li><a href="index.html">home</a></li>
						<li><a href="services.html">services</a></li>
						<li><a href="farmacii.html">farmacii</a></li>
						<li><a href="career.html">career</a></li>
						<li><a href="news.html">News</a></li>
						<li><a href="contact.html">contact</a></li>
					</ul>

					<div class="lang-wrap">
						<div class="nice-select" tabindex="0">
							<img src="img/lang-1.svg" alt="">
							En
							<ul class="list">
								<li class="option selected" ><a href="#"><img src="img/lang-1.svg" alt="">En</a></li>
								<li class="option"><a href="#"><img src="img/lang-2.jpg" alt="">RO</a></li>
								<li class="option"><a href="#"><img src="img/lang-3.png" alt="">RU</a></li>
							</ul>
						</div>
					</div>

					<div class="open-menu">
						<a href="#">
							<span></span>
							<span></span>
							<span></span>
						</a>
					</div>
				</nav>
			</div>
		</div>
  </header>

	<div class="menu-responsive" id="menu-responsive" style="display: none">
		<div class="top">
			<div class="close-menu">
				<a href="#"><img src="img/close.svg" alt=""></a>
			</div>
		</div>
		<div class="wrap">
			<div class="logo-wrap">
				<a href="index.html">
					<img src="img/logo.svg" alt="">
				</a>
			</div>
			<nav class="mob-menu">
				<ul>
					<li><a href="index.html">home</a></li>
					<li><a href="services.html">services</a></li>
					<li><a href="farmacii.html">farmacii</a></li>
					<li><a href="career.html">career</a></li>
					<li><a href="news.html">News</a></li>
					<li><a href="contact.html">contact</a></li>
				</ul>
			</nav>
		</div>
	</div>

	<main>



		<section class="page-article">
			<div class="bg"></div>
			<div class="content-width">

				<ul class="breadcrumb">
					<li><a href="index.html">Home</a><span><img src="img/icon-11.svg" alt=""></span> </li>
					<li><a href="index.html">News</a><span><img src="img/icon-11.svg" alt=""></span> </li>
					<li>Small molecule drug shows promise in rare disease</li>
				</ul>

				<div class="top">
					<h1>Small molecule drug shows promise in rare disease</h1>
					<p>In a Phase II trial, the small-molecule drug CBL-514 demonstrated significant reduction in lipoma size and pain improvement in Dercum’s disease, a rare disorder.</p>
				</div>
				
				<div class="content">
					<figure>
						<img src="img/img-6.jpg" alt="">
					</figure>
					<ol>
						<li>
							<h4>Results from the CBL-514 Phase II study</h4>
							<p>The CBL-0201DD Phase II study evaluating the first-in-class small-molecule drug CBL-514 for Dercum’s disease, a rare disorder, has demonstrated significant efficacy in reducing lipoma size and complete clearance.</p>
						</li>
						<li>
							<h4>The study for Dercum’s disease</h4>
							<p>Evaluated the efficacy and safety of CBL-514 injections in twelve participants. As a primary endpoint, painful lipomas dimension in the high-dose group was reduced by 51.3 percent and 54.7 percent at 4 and 8 weeks after CBL-514 treatments.</p>

							<h2>Future clinical progression for the first-in-class small-molecule drug</h2>
							<p>Painful lipomas dimension in the low-dose group was reduced by 40.0 percent and 34.7 percent at 4 and 8 weeks after CBL-514 treatments.</p>
						</li>
						<li>
							<h4>90.3 percent of painful lipomas in the high-dose group</h4>
							<p>Showed dimensions reduction after CBL-514 treatments when compared to baseline. In the Dercum’s disease patients who received the high-dose, 64.5 percent of painful lipomas demonstrated complete clearance or dimensions reduction of more than 50 percent after CBL-514 treatments compared to baseline.</p>

							<ol>
								<li>1. 38.7 percent of painful lipomas in the high-dose group</li>
								<li>2. The Global Dercum’s Disease Market Research Report</li>
								<li>3. The global Dercum’s disease treatment market size in 2021 was $11.3 billion</li>
							</ol>
						</li>
					</ol>
					
					<figure>
						<img src="img/img-7.jpg" alt="">
					</figure>

					<blockquote>
						<span>CBL-514 is the first and only product to show clinically meaningful and statistically significant in painful lipomas complete clearance or dimensions reduction of more than 50 percent</span>”
						<p>— Olivie Rhye, financial analyst</p>
					</blockquote>

					<h2>Dercum’s disease treatment</h2>

					<p>The global Dercum’s disease treatment market size in 2021 was $11.3 billion. With a compound annual growth rate (CAGR) of 6.76 percent, the global market of Dercum’s disease treatment in 2030 is predicted to grow to $19.95 billion.</p>

					<ul>
						<li>Detailed efficacy and safety</li>
						<li>Dercum’s disease CBL-0201DD study</li>
						<li>The Journal of Rare Diseases</li>
						<li>Based on the research findings,</li>
					</ul>

					<h2>Conclusions</h2>
					<p>Caliway is currently planning for CBL-0202DD Phase IIb study IND application to further investigate CBL-514.</p>
				</div>
			</div>
		</section>

		<section class="news">
			<div class="content-width">

				<h2>Related News</h2>
				<div class="btn-wrap-last">
					<a href="#" class="btn-default">See all<img src="img/icon-1.svg" alt=""></a>
				</div>
				<div class="content ">
					<div class="item" data-aos="fade-up">
						<a href="#">
							<figure>
								<img src="img/img-4-1.jpg" alt="">
							</figure>
							<div class="text-wrap">
								<p class="h6">European Pharmaceutical Review Issue 4 2023</p>
								<p class="text">Get a production cloud provisioned with fully-managed structure</p>
							</div>
						</a>
					</div>
					<div class="item" data-aos="fade-up" data-aos-delay="50">
						<a href="#">
							<figure>
								<img src="img/img-4-2.jpg" alt="">
							</figure>
							<div class="text-wrap">
								<p class="h6">Route scouting for a cost-effective process development</p>
								<p class="text">Watch this webinar to discover how route scouting and polymorph screening </p>
							</div>
						</a>
					</div>
					<div class="item" data-aos="fade-up" data-aos-delay="100">
						<a href="#">
							<figure>
								<img src="img/img-4-3.jpg" alt="">
							</figure>
							<div class="text-wrap">
								<p class="h6">Small molecule drug shows promise in rare disease</p>
								<p class="text">Process development is often undervalued in the early drug development phases due to time or budget constraints. Often, medicinal chemistry processes are incompatible for scale-up and – if insufficient effort is expended in developing a suitable route – these inefficient processes are used to generate material for absorption, distribution, metabolism and excretion (ADME)/Tox or early clinical studies</p>
							</div>
						</a>
					</div>
					<div class="item" data-aos="fade-up" data-aos-delay="150">
						<a href="#">
							<figure>
								<img src="img/img-4-4.jpg" alt="">
							</figure>
							<div class="text-wrap">
								<p class="h6">Pfizer’s migraine medicine recommended by NICE</p>
								<p class="text">The National Institute for Health and Care Excellence (NICE) has published final draft guidance on Pfizer’s Rimegepant, recommending it for the first time as a treatment for acute migraines.</p>
							</div>
						</a>
					</div>
				</div>
			</div>
		</section>
	</main>

	<footer>
		<div class="content-width">
			<div class="content">
				<div class="logo-wrap">
					<a href="index.html">
						<img src="img/logo-footer.svg" alt="">
					</a>
				</div>
				<nav class="footer-menu">
					<ul>
						<li><a href="index.html">home</a></li>
						<li><a href="services.html">services</a></li>
						<li><a href="farmacii.html">farmacii</a></li>
						<li><a href="career.html">career</a></li>
						<li><a href="news.html">News</a></li>
						<li><a href="contact.html">contact</a></li>
					</ul>
					<div class="form-wrap">
						<form action="#" class="form-subscribe">
							<label for="subscribe"></label>
							<input type="email" id="subscribe" name="subscribe" placeholder="Email">
							<button type="submit" class="btn-default">Subscribe <img src="img/icon-1.svg" alt=""></button>
						</form>
					</div>
				</nav>

				<div class="bottom">
					<p>© Farmina 2023</p>
				</div>
			</div>
		</div>
	</footer>

	<div id="call" class="popup-default call-popup" style="display: none">
		<div class="popup-main">
			<h2>Request a call</h2>
			<form action="#" class="default-form">
				<div class="input-wrap">
					<label for="name">Full name</label>
					<input type="text" name="name" id="name" placeholder="Enter your full name">
				</div>
				<div class="input-wrap input-wrap-tel">
					<label for="tel">Enter phone number</label>
					<input type="text" name="tel" id="tel" placeholder="123">
				</div>
				<div class="select-block ">
					<label class="form-label" for="select">Purpose of call</label>
					<select id="select">
						<option value="0" selected disabled>Choose propose of call</option>
						<option value="1">Sales</option>
						<option value="2">Certification</option>
						<option value="3">Sales</option>
					</select>
				</div>
				<div class="input-wrap-submit">
					<button type="submit" class="btn-default send">Submit</button>
				</div>
			</form>
		</div>
	</div>

	<div id="send-ok" class="popup-default send-popup" style="display: none">
		<div class="popup-main">
			<figure>
				<img src="img/icon-4.svg" alt="">
			</figure>
			<h2>Thank you for your request</h2>
			<p>Our manager will contact you within 3 working days</p>
		</div>
	</div>




  <script src="js/jquery.min.js"></script>
	<script src="js/swiper.js"></script>
	<script src="js/jquery.fancybox.min.js"></script>
	<script src="js/jquery.nice-select.min.js"></script>
	<script src="js/jquery.animateNumber.min.js"></script>
	<script src="js/intlTelInput.min.js"></script>
	<script src="js/aos.js"></script>
	<script src="js/cuttr.min.js"></script>
	<script src="js/script.js"></script>
</body>
</html>